Nitisinone Dipharma (Nitisinone)

Nitisinone blocks the enzyme p‑hydroxyphenylpyruvate dioxygenase (HPPD) in the tyrosine degradation pathway. By inhibiting this step, it prevents the formation of downstream toxic metabolites such as fumarylacetoacetate, thereby protecting liver and kidney tissues from damage.

The specific dose of Nitisinone Dipharma is determined by the prescribing physician based on the patient’s age, weight, disease severity, and laboratory parameters. Dosage adjustments are made according to clinical response and safety monitoring.

The safety of Nitisinone in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and necessary import documentation.

Nitisinone is the only disease‑modifying therapy that directly inhibits the HPPD enzyme, addressing the metabolic cause of hereditary tyrosinemia type I. Alternative approaches, such as liver transplantation, manage complications but do not correct the underlying metabolic defect.

Store the product at temperatures below 25 °C, in its original packaging, and protect it from moisture and direct sunlight. Do not refrigerate or freeze unless the label specifically indicates otherwise.

Nitisinone Dipharma is taken orally, usually as a tablet or capsule, with or without food as directed by the prescribing clinician. The exact administration schedule is individualized for each patient.

Serious risks include hepatic failure, severe neutropenia, and hypersensitivity reactions such as anaphylaxis. Patients should be monitored regularly for liver function, blood counts, and any signs of allergic response.

Patients with known hypersensitivity to Nitisinone or any component of the formulation should avoid the drug. Caution is also advised for individuals with severe liver or kidney impairment, and the medication should be used only under specialist supervision in such cases.